tradingkey.logo

Check Cap Ltd

CHEK
1.610USD
0.0000.00%
Handelsschluss 02/06, 16:00ETKurse um 15 Minuten verzögert
9.42MMarktkapitalisierung
VerlustKGV TTM

Check Cap Ltd

1.610
0.0000.00%

mehr Informationen über Check Cap Ltd Unternehmen

Check Cap Ltd is an Israel-based clinical-stage medical diagnostics company. Check Cap Ltd develops C-Scan, patient-friendly preparation-free test designed to detect polyps before they may transform into cancer to enable early intervention and cancer prevention. It's capsule-based screening technology aims to increase screening adherence worldwide. The system utilizes ultra-low-dose X- rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities. C-Scan is non-invasive capsule that is propelled through the gastrointestinal tract by natural motility. C-Scan is comprised of three main components: C-Scan Cap, an ingestible X-ray scanning capsule; C-Scan Track, three miniaturized patches worn on the patient’s back for integrated positioning, control and data recording; and C-Scan View, a proprietary software to process and represent 2D and 3D maps of the inner surface of the colon.

Check Cap Ltd Informationen

BörsenkürzelCHEK
Name des UnternehmensCheck Cap Ltd
IPO-datumFeb 19, 2015
CEOOvadia (Alex)
Anzahl der mitarbeiter- -
WertpapierartOrdinary Share
GeschäftsjahresendeFeb 19
Addresse29 Abba Hushi Ave.
Stadt
BörseNASDAQ OMX - NASDAQ BASIC
LandIsrael
Postleitzahl3009000
Telefon97248303401
Websitehttps://check-cap.com/
BörsenkürzelCHEK
IPO-datumFeb 19, 2015
CEOOvadia (Alex)

Führungskräfte von Check Cap Ltd

Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Yoav Kimchy, Ph.D.
Dr. Yoav Kimchy, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
Mr. Alex Ovadia
Mr. Alex Ovadia
Chief Executive Officer
Chief Executive Officer
--
--
Mr. Steven J. Hanley
Mr. Steven J. Hanley
Chairman of the Board
Chairman of the Board
--
--
Mr. Yuval Yanai
Mr. Yuval Yanai
Independent Director
Independent Director
--
--
Mr. XiangQian (XQ) Lin
Mr. XiangQian (XQ) Lin
Independent Director
Independent Director
--
--
Dr. Mary Jo Gorman, M.D.
Dr. Mary Jo Gorman, M.D.
Independent Director
Independent Director
--
--
Mr. Boaz Shpigelman
Mr. Boaz Shpigelman
Vice President - Research and Development
Vice President - Research and Development
--
--
Ms. Clara Ezed
Ms. Clara Ezed
Independent Director
Independent Director
--
--
Mr. Joshua (Shuki) Belkar
Mr. Joshua (Shuki) Belkar
Vice President - Operations
Vice President - Operations
--
--
Mr. Israel Hershko
Mr. Israel Hershko
Vice President - Quality Assurance and Regulatory Affairs
Vice President - Quality Assurance and Regulatory Affairs
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Yoav Kimchy, Ph.D.
Dr. Yoav Kimchy, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
Mr. Alex Ovadia
Mr. Alex Ovadia
Chief Executive Officer
Chief Executive Officer
--
--
Mr. Steven J. Hanley
Mr. Steven J. Hanley
Chairman of the Board
Chairman of the Board
--
--
Mr. Yuval Yanai
Mr. Yuval Yanai
Independent Director
Independent Director
--
--
Mr. XiangQian (XQ) Lin
Mr. XiangQian (XQ) Lin
Independent Director
Independent Director
--
--
Dr. Mary Jo Gorman, M.D.
Dr. Mary Jo Gorman, M.D.
Independent Director
Independent Director
--
--

Umsatzaufteilung

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Aktionärsstatistik

Aktualisiert: 5 hours ago
Aktualisiert: 5 hours ago
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
EquityLine Alternate Assets GP Inc
10.46%
Ramanathan (Vijay)
4.94%
Symetryx Corp
4.65%
BNP Paribas Securities Corp. North America
0.30%
Dimensional Fund Advisors, L.P.
0.12%
Andere
79.53%
Aktionäre
Aktionäre
Anteil
EquityLine Alternate Assets GP Inc
10.46%
Ramanathan (Vijay)
4.94%
Symetryx Corp
4.65%
BNP Paribas Securities Corp. North America
0.30%
Dimensional Fund Advisors, L.P.
0.12%
Andere
79.53%
Aktionärstypen
Aktionäre
Anteil
Corporation
15.11%
Individual Investor
4.94%
Research Firm
0.41%
Investment Advisor/Hedge Fund
0.16%
Investment Advisor
0.11%
Bank and Trust
0.05%
Andere
79.22%

Institutionelle Beteiligung

Aktualisiert: Mon, Dec 8
Aktualisiert: Mon, Dec 8
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
31
46.22K
2.97%
--
2025Q3
31
46.22K
2.97%
-83.61K
2025Q2
30
129.91K
3.13%
+25.59K
2025Q1
31
104.32K
4.46%
-156.41K
2024Q4
32
147.67K
2.55%
+134.65K
2024Q3
33
13.02K
3.40%
+4.10K
2024Q2
36
9.37K
3.50%
-1.09K
2024Q1
41
13.66K
3.76%
-206.06K
2023Q4
43
68.48K
6.43%
+25.25K
2023Q3
45
28.34K
6.39%
+11.71K
Mehr Anzeigen

Aktionärsaktivitäten

Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
EquityLine Alternate Assets GP Inc
762.72K
10.46%
--
--
Dec 31, 2024
Ramanathan (Vijay)
360.00K
4.94%
--
--
Dec 31, 2024
Symetryx Corp
338.63K
4.65%
--
--
Dec 31, 2024
BNP Paribas Securities Corp. North America
21.64K
0.3%
+1.50K
+7.45%
Sep 30, 2025
Dimensional Fund Advisors, L.P.
8.96K
0.12%
--
--
Sep 30, 2025
UBS Financial Services, Inc.
476.00
0.01%
-5.47K
-91.99%
Sep 30, 2025
Morgan Stanley & Co. LLC
6.30K
0.09%
+2.30K
+57.44%
Sep 30, 2025
National Bank of Canada
3.27K
0.04%
--
--
Sep 30, 2025
Geode Capital Management, L.L.C.
2.93K
0.04%
--
--
Nov 30, 2025
J.P. Morgan Securities LLC
1.50K
0.02%
-210.00
-12.28%
Sep 30, 2025
Mehr Anzeigen

Verbundene ETFs

Name
Anteil
Keine Daten

Dividende

In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten

Aktien-Split

Datum
Ex-Dividendentag
Art
Verhältnis
Nov 23, 2022
Merger
20→1
Nov 23, 2022
Merger
20→1
Nov 23, 2022
Merger
20→1
Nov 23, 2022
Merger
20→1
Datum
Ex-Dividendentag
Art
Verhältnis
Nov 23, 2022
Merger
20→1
Nov 23, 2022
Merger
20→1
Nov 23, 2022
Merger
20→1
Nov 23, 2022
Merger
20→1
KeyAI